News
| 2 min read
First patient has been dosed in Phase 3 avatrombopag study for the treatment of ITP in children
| 5 min read
An ounce of prevention was certainly worth the pound of its eventual cure when it comes to assigning inventions
| 2 min read
Aeterna has obtained an exclusive license from The University of Sheffield to IP relating to parathyroid hormone fusion polypeptides
| 3 min read
New collaborations will give I-Mab access to cutting edge technology platforms for developing novel drug molecules
| 3 min read
Yumanity's YTX-7739 prevents motor function deficits, leads to improved survival of dopaminergic neurons in Parkinson’s disease mouse model
| 3 min read
Merck reports Phase 1 data of its subdermal implant for pre-exposure prophylaxis of HIV-1 infection
| 3 min read
Selexis and BITT enter agreement to advance BITT’s TNFR2 antagonist antibody therapy
| 4 min read
Dosing every eight weeks instead of four still showed continued virologic suppression to 96 weeks
| 2 min read
FDA grants Fast Track designations to three of Passage Bio’s gene therapy candidates for CNS disorders
| 2 min read
Akari Therapeutics enters agreement with US Army Institute of Surgical Research for nomacopan
| 3 min read
Researchers discover how malignant rhabdoid tumors begin, and identify potential treatments
